Risk Stratification of Rapid Disease Progression in Children With Crohn’s Disease

Overview

The purpose of this study for children with a new diagnosis of Crohn's disease is to identify biomarkers found in the blood or stool to help predict which children are at risk of developing complications.

Full Title of Study: “Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn’s Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2020

Detailed Description

It is estimated that between 15-20% of children with Crohn's disease will develop complications that can require surgery within the first three years of diagnosis. The purpose of this study for children with a new diagnosis of Crohn's disease is to identify biomarkers found in the blood or stool to help predict which children are at risk of developing complications. A total of 2000 children with newly-diagnosed Crohn's disease will be enrolled within 30 days of diagnosis. Up to 28 medical sites in the United States and Canada will participate in the study.

Arms, Groups and Cohorts

  • Observation
    • Children newly diagnosed with Crohn’s disease.

Clinical Trial Outcome Measures

Primary Measures

  • Identify demographic, clinical, microbial, genetic, and/or immunologic risk factors influencing the likelihood of rapid development of complicated disease phenotypes manifested as penetrating or stricturing disease and need for surgery.
    • Time Frame: 3 years

Secondary Measures

  • Develop and validate risk stratification by stratifying patients into different levels of risk at diagnosis based on clinical, demographic, host microbial ecology, immune, and genetic determinants.
    • Time Frame: 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Males and females younger than 17 years of age (before their 17th birthday). An upper limit of 17 years of age was selected as important inclusion criteria to maximize the number of potential subjects that would be diagnosed and followed by a pediatric gastroenterologist for at least 3 years. – Confirmed or suspected diagnosis of Crohn's disease based on standardized diagnostic criteria. The enrollment should occur within 30 days of diagnosis. – Able to provide written informed consent or the ability to obtain written informed consent from the parents or patient's legal guardian in conjunction with youth assent. – Consented to have specimens tested for genetics and immune responses. – Access to follow-up data for a minimum of 36 months after diagnosis. – Final eligibility will be determined by the health professionals conducting this clinical trial. Exclusion Criteria:

  • Infectious colitis. – Final eligibility will be determined by the health professionals conducting this clinical trial.

Gender Eligibility: All

Minimum Age: 5 Days

Maximum Age: 16 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Emory University
  • Collaborator
    • Crohn’s and Colitis Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Subra Kugathasan, MD, Professor – Emory University
  • Overall Official(s)
    • Subra Kugathasan, MD, Principal Investigator, Emory University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.